Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case

Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP) previously under development as a lipid‐modifying agent that reduces LDL‐cholesterol and increases HDL‐cholesterol in hypercholesterolemic patients. Anacetrapib demonstrates a long terminal half‐life and accumulates in adipose...

Descripción completa

Detalles Bibliográficos
Autores principales: Johns, Douglas G., Wang, Sheng‐Ping, Rosa, Raymond, Hubert, James, Xu, Suoyu, Chen, Ying, Bateman, Thomas, Blaustein, Robert O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857080/
https://www.ncbi.nlm.nih.gov/pubmed/31832204
http://dx.doi.org/10.1002/prp2.543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857080/
https://www.ncbi.nlm.nih.gov/pubmed/31832204
http://dx.doi.org/10.1002/prp2.543

Ejemplares similares